ThermoGenesis Corp. Reports Fourth Quarter and Fiscal Year 20...( COMPANY PROVIDES UPDAT...)

COMPANY PROVIDES UPDATE ON CORPORATE STRATEGY

RANCHO CORDOVA, Calif., Sept. 12 /PRNewswire-FirstCall/ -- ThermoGenesis Corp. (Nasdaq: KOOL), a leading supplier of enabling technologies for stem cell therapy, today reported results for the fourth quarter and all of fiscal 2007.

Revenues for the quarter ended June 30, 2007 were $3,520,000 compared with revenues of $3,557,000 for the fourth quarter of fiscal 2006. Revenues related to the Company's stem cell therapy activities were $2,443,000 versus $2,708,000 in the same period a year ago. Revenues from the sale of BioArchive and AutoXpress Platform(TM) (AXP) disposables for the fourth quarter of fiscal 2007 were $1,246,000 versus $680,000 in the same period a year ago. The Company sold three BioArchive(R) Systems in the quarter versus seven in the fourth quarter a year ago.

The Company reported a net loss of $2,613,000, or $0.05 per share, in the fourth quarter of fiscal 2007, compared with a net loss of $1,482,000, or $0.03 per share, in the same period a year ago.

For all of fiscal 2007, revenues were $16,751,000, within the range provided by the Company in its press release on July 30, 2007. Revenues for fiscal 2007 increased 39 percent over revenues of $12,048,000 in fiscal 2006. The Company reported a net loss of $6,776,000, or $0.12 per share, compared with a net loss of $6,142,000, or $0.12 per share, in fiscal 2006. Weighted shares outstanding at June 30, 2007 increased to 55.2 million shares compared with 49.6 million at June 30, 2006, primarily the result of an equity offering of 8.8 million shares completed in March 2006.

"ThermoGenesis had a solid year, recording a 39 percent increase in revenues, achieving key clini
'/>"/>